On June 29, 2023, the 9th China Biopharmaceutical Innovation Conference and the Huayi Pharma 2023 China Biopharmaceutical Industry Value Awards Ceremony, hosted by Wanyee Medical, were grandly held in Suzhou. Canton Biologics was selected as one of the Top 10 Most Growth‑oriented CDMO Enterprises, thanks to its outstanding technological innovation capabilities and market development potential.
(Image placeholder)
Sixth from left: Wei Qingkun, representative of Canton Biologics
The conference featured more than 10 specialized forums, inviting over 200 industry leaders and more than 1,800 expert attendees. It provided comprehensive opportunities for networking and exchange through keynote speeches, roundtable discussions, private seminars, award announcements, and poster presentations. The award list was based on the enterprise growth evaluation criteria developed by Huayi Research Institute over many years, combined with questionnaire surveys, corporate interviews, data analysis, and verification. The evaluation panel standardized and quantitatively assessed the dynamic data of shortlisted biopharmaceutical companies to select enterprises with significant industry value for the year, forming an objective third‑party evaluation list.
In recent years, Canton Biologics has grown rapidly, demonstrating strong growth potential. The company has continuously increased its R&D investment, expanded its R&D and production bases and team size, and strengthened its technical capabilities in CMC development for innovative drugs and commercial manufacturing. In 2022, Canton Biologics’ technological capabilities reached a new level, achieving significant breakthroughs particularly in the IgM expression platform, host cell engineering, high‑density cell culture, novel formulations, and analytical methods. Its GMP manufacturing centers were put into operation as scheduled, and Phase III clinical and commercial manufacturing began serving international markets. The company has served numerous top biopharmaceutical companies both domestically and internationally. In 2023, Canton Biologics continued to expand its business scope, establishing a global clinical supply service center in Shanghai to provide services including clinical supply management, comparator drug procurement, primary and secondary packaging of clinical supplies, labeling, import/export permit application, global cold chain storage and distribution, as well as return and destruction services – offering partners more comprehensive CDMSO technical services.
With its solid capabilities driving growth, Canton Biologics’ recognition at this awards ceremony reflects not only the affirmation of industry experts but also the recognition of peers. We will continue to uphold our values of “Reliable, Efficient, Innovative” and provide our clients with excellent technical services, jointly promoting the rapid development of the biotechnology industry.
